ClinicalTrials.gg
CompletedNCT02282813Updated Sep 29, 2016Results posted

Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002

A Phase 3 interventional study of CTAP101 Capsules and Calcitriol in Chronic Kidney Disease, Hyperparathyroidism, Secondary and Vitamin D Deficiency, sponsored by OPKO Health, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-29.

Sponsored by OPKO Health, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
298
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone (iPTH) and correcting vitamin D insufficiency in stage 3 or 4 chronic kidney disease patients.

Read the detailed description

Only subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 are eligible to participate in this extension study. This is a phase 3, open-label study of CTAP101 Capsules, with and without add-on vitamin D hormone therapy.

02

Conditions studied

  • Chronic Kidney Disease
  • Hyperparathyroidism, Secondary
  • Vitamin D Deficiency

Keywords

  • Parathyroid Diseases
  • Renal Insufficiency
  • Kidney Failure, Chronic
  • Hyperparathyroidism, Secondary
  • Vitamin D
  • Hyperparathyroidism
  • Kidney Diseases
  • Kidney Failure
  • Renal Insufficiency, Chronic
03

In context

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

This study's enrollment of 298 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed either of the phase 3 double-blind, placebo-controlled studies, CTAP101-CL-3001 or CTAP101-CL-3002
  • Taking no more than 1000 mg/day of elemental Ca and willing/able to remain on this dose for the duration of the study
  • Taking no more than 1600 IU/dose vitamin D (ergocalciferol or cholecalciferol) therapy and willing/able to remain on a stable dose of vitamin D during the study
  • Willing and able to comply with study instructions and to commit to all clinic visits for the duration of the study
  • Female subjects of must be neither pregnant nor lactating and must have a negative urine pregnancy test
  • All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study
  • Have the ability to read and understand subject Form (ICF). Subjects or their legal representatives must sign the ICF.

Exclusion criteria

Exclusion Criteria:

  • Use of pharmacological dose of ergocalciferol and cholecalciferol (monthly equivalent of 50,000 IU or 1250 µg, eg, Drisdol®) or bisphosphonate therapy
  • Use of other bone metabolism therapy (with the exception of stable doses of bisphosphonates and denosumab [Xgeva® and Prolia®]) that may interfere with study endpoints
  • Concomitant serious illness or medical condition, such as , , significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis that in the opinion of the investigator may worsen and/or interfere with participation in the study
  • Neurological/psychiatric disorder, including psychotic disorder or dementia, or any condition reason which, in the opinion of the investigator makes adherence to a treatment or follow-up schedule unlikely
  • Known or suspected to any of the constituents of either product (CTAP101) or adjunctive vitamin D hormone therapy
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
298 participants (actual)

Study arms

  • Experimental
    CTAP101 Capsules alone

    CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks

    Drug: CTAP101 Capsules

  • Experimental
    CTAP101 Capsules +calcitriol

    CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks

    Drug: CTAP101 Capsules · Drug: Calcitriol

  • Experimental
    CTAP101 Capsules +doxercalciferol

    CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks

    Drug: CTAP101 Capsules · Drug: Doxercalciferol

  • Experimental
    CTAP101 Capsules +paricalcitol

    CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks

    Drug: CTAP101 Capsules · Drug: Paricalcitol

Interventions

  • At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily

    Also known as: Calcifediol

  • At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily

    Also known as: calcifediol

  • At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily

    Also known as: calcifediol

  • At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily

    Also known as: calcifediol

06

What researchers measure

Primary outcomes

  1. Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)

    Number of subjects in the intent to treat population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders

    Time frame: up to 6 months

Secondary outcomes

  1. Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)

    Number of subjects in the per protocol population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders

    Time frame: up to 6 months

  2. Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT)

    Number of Participants in the Intent to Treat Population with serum 25-hydroxyvitamin D \>/= 30 ng/mL at End of Treatment (EOT)

    Time frame: up to 6 months

  3. Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT)

    Number of Participants in the per protocol population with serum 25-hydroxyvitamin D \>/= 30 ng/mL at End of Treatment (EOT)

    Time frame: up to 6 months

07

Results

Posted Aug 17, 2016

Participant flow

Subjects could enroll in extension study after completing trials CTAP101-CL-3001 or CTAP101-CL-3002. Subjects from 68 sites participated with at least 1 subject enrolled in the extension per site. Three sites participated in both blinded trials.

Participant flow — Overall Study
MilestoneCTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Not Randomized; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive
Started10315342
Completed9113039
Not completed12233
Withdrew: Withdrawal by subject450
Withdrew: Adverse event3101
Withdrew: Subject non-compliance140
Withdrew: Physician decision031
Withdrew: Lost to follow-up201
Withdrew: Serum ca >/=11.0mg/dl100
Withdrew: Lack of efficacy100
Withdrew: Administrative reasons010

Outcome measures

PrimaryNumber of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)

Number of subjects in the intent to treat population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders

Time frame:
up to 6 months
Reported as:
Number · participants
Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)
participantsCTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Not Randomized; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive
Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)346630
Statistical analysis
  • CTAP101 Capsules (Not Randomized; 6 Mos Treatment) vs CTAP101 Capsules (Not Randomized; 12 Mos Treatment) · Cochran-Mantel-Haenszel · p = 0.1041
SecondaryNumber of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)

Number of subjects in the per protocol population with a mean reduction in plasma intact parathyroid hormone (iPTH) of \>/= 30% from pretreatment baseline values at end of treatment (EOT), classified as responders

Time frame:
up to 6 months
Reported as:
Number · participants
Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)
participantsCTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Not Randomized; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive
Number of Participants in the Per Protocol Population With Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT)346429
Statistical analysis
  • CTAP101 Capsules (Not Randomized; 6 Mos Treatment) vs CTAP101 Capsules (Not Randomized; 12 Mos Treatment) · Cochran-Mantel-Haenszel · p = .0503
SecondaryNumber of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT)

Number of Participants in the Intent to Treat Population with serum 25-hydroxyvitamin D \>/= 30 ng/mL at End of Treatment (EOT)

Time frame:
up to 6 months
Reported as:
Number · participants
Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT)
participantsCTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Not Randomized; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive
Number of Participants in the Intent to Treat Population With Normal Serum 25-hydroxyvitamin D at End of Treatment (EOT)8712438
Statistical analysis
  • CTAP101 Capsules (Not Randomized; 6 Mos Treatment) vs CTAP101 Capsules (Not Randomized; 12 Mos Treatment) · Cochran-Mantel-Haenszel · p = 0.4817
SecondaryNumber of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT)

Number of Participants in the per protocol population with serum 25-hydroxyvitamin D \>/= 30 ng/mL at End of Treatment (EOT)

Time frame:
up to 6 months
Reported as:
Number · participants
Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT)
participantsCTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Not Randomized; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive
Number of Participants in the Per Protocol Population With NormalSerum 25-hydroxyvitamin D at End of Treatment (EOT)8612037
Statistical analysis
  • CTAP101 Capsules (Not Randomized; 6 Mos Treatment) vs CTAP101 Capsules (Not Randomized; 12 Mos Treatment) · Cochran-Mantel-Haenszel · p = 0.8086

Adverse events

Collected over 6 months from initiation of treatment through end of treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CTAP101 Capsules (Not Randomized; 6 Mos Treatment)—18/103 (17.5%)36/103 (35%)
CTAP101 Capsules (Not Randomized; 12 Mos Treatment)—33/153 (21.6%)54/153 (35.3%)
CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive—9/42 (21.4%)22/42 (52.4%)
Most frequent serious events
Showing 10 of 73
Most frequent serious events
EventCTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Not Randomized; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive
Cardiac failure congestiveCardiac disorders3/1032/1531/42
DiarrhoeaGastrointestinal disorders0/1030/1531/42
Upper gastrointestinal haemorrhageGastrointestinal disorders0/1030/1531/42
CellulitisInfections and infestations1/1032/1531/42
Urinary tract infectionInfections and infestations1/1032/1531/42
Blood creatinine phosphokinase MB increasedInvestigations0/1030/1531/42
HyperglycaemiaMetabolism and nutrition disorders0/1030/1531/42
OsteoarthritisMusculoskeletal and connective tissue disorders0/1031/1531/42
EncephalopathyNervous system disorders0/1030/1531/42
Hypoglcaemic seizureNervous system disorders0/1030/1531/42
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Not Randomized; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+Adjunctive
HyperphosphatemiaMetabolism and nutrition disorders2/1033/1534/42
NauseaGastrointestinal disorders8/1035/1532/42
OedemaGeneral disorders2/1032/1533/42
Blood creatinine increasedInvestigations3/1036/1533/42
HypoglycaemiaMetabolism and nutrition disorders1/1033/1533/42
HyperkalaemiaMetabolism and nutrition disorders1/1030/1533/42
CoughRespiratory, thoracic and mediastinal disorders5/1034/1533/42
HypertensionVascular disorders4/1036/1533/42
AnaemiaBlood and lymphatic system disorders7/1039/1532/42
ConstipationGastrointestinal disorders7/1036/1530/42

Baseline characteristics

Intent to treat population: includes subjects receiving CTAP101 capsules only in the extension trial (up to 6 months total active therapy, subjects receiving up to 12 months receiving CTAP101 capsules (6 months in the previous trials and up to 6 months in the extension) with or without being randomized to CTAP101 capsules plus adjunctive therapy.

Age, Continuous
Age, Continuous(years)CTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Monotherapy; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+AdjunctiveTotal
Mean64.7 ± 10.7866.9 ± 9.8365.0 ± 12.3465.9 ± 10.56
Sex: Female, Male
Sex: Female, Male(Participants)CTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Monotherapy; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+AdjunctiveTotal
Female558514154
Male486828144
Region of Enrollment
Region of Enrollment(participants)CTAP101 Capsules (Not Randomized; 6 Mos Treatment)CTAP101 Capsules (Monotherapy; 12 Mos Treatment)CTAP101 Caps 2 x 30 mcg Daily for 12 wk+AdjunctiveTotal
United States10315342298
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 3 months after primary completion. A results delay was requested in Jun 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2014
First posted
Nov 4, 2014
Start
Apr 2013
Primary completionActual
May 2015
CompletionActual
May 2015
Results delay requested
Jun 21, 2016
Results first posted
Aug 17, 2016
Last update
Sep 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02282813
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Nov 4, 2014
Start date
Apr 2013
Primary completion
May 2015
Completion
May 2015
Results posted
Aug 17, 2016
Last update
Sep 29, 2016

Study contacts

Joel Melnick, MD
study director · OPKO Renal

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Modified-release Calcifediol Capsule

Start the discussion